Jiayi Huang
NRG Oncology · Washington University School of Medicine · Yale University Cancer Center LAO
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jiayi Huang as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:21 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07452458 · Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated GlioblastomaNRG Oncology · recruiting · Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma · principal investigator
- Early Ph1NCT06831526 · Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed GlioblastomaWashington University School of Medicine · recruiting · Glioblastoma · principal investigator
- N/ANCT05393258 · Temporally-modulated Pulsed Radiation Therapy (TMPRT) After Prior EBRT for Recurrent IDH-mutant GliomasWashington University School of Medicine · completed · Astrocytoma, Oligodendroglioma, Adult, Glioma, Malignant · principal investigator
- N/ANCT04975139 · Cognitive Changes of IDH-mutant and IDH-wildtype Glioma Patients After Chemoradiotherapy With Radiation Dose to the Resting State NetworksWashington University School of Medicine · active not recruiting · Glioma · principal investigator
- Ph1NCT04757662 · Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV AstrocytomaWashington University School of Medicine · completed · Grade III Astrocytoma, Grade IV Astrocytoma, Astrocytoma, Grade IV · principal investigator
- Ph1/Ph2NCT03604978 · Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III MeningiomaNational Cancer Institute (NCI) · active not recruiting · Grade 2 Meningioma, Grade 3 Meningioma, Recurrent Meningioma · principal investigator
- Ph1NCT03267836 · Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory MeningiomaWashington University School of Medicine · terminated · Meningioma, Meningioma, Adult · principal investigator
- Ph2NCT03034135 · Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent GlioblastomaCantex Pharmaceuticals · completed · Recurrent Glioblastoma · study chair
- Ph1/Ph2NCT02715609 · Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed GlioblastomaWashington University School of Medicine · completed · Glioblastoma Multiforme · principal investigator
- Ph1NCT02311556 · Response of Brain Metastases After Gamma-Knife Radiosurgery Using Dynamic Susceptibility-weighted Contrast-enhanced Perfusion Magnetic Resonance ImagingWashington University School of Medicine · completed · Brain Metastases · principal investigator
- Early Ph1NCT01907165 · Disulfiram in Treating Patients With Glioblastoma Multiforme After Radiation Therapy With TemozolomideWashington University School of Medicine · completed · Glioblastoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:21 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- NRG Oncology NCORP Research BaseUG1CA189867 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Deborah Watkins Bruner, Lisa A. Kachnic · fiscal years 2014 to 2026Named on NCT07452458
- Supplement to Extend Funds for Grant #UM1CA186689 VICKtOrY Early Clinical Trials ConsortiumUM1CA186689 · NCI · YALE UNIVERSITY · PI Patricia M. LoRusso · fiscal years 2014 to 2026Named on NCT03604978
- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)UM1CA186704 · NCI · DUKE UNIVERSITY · PI JAMES L. ABBRUZZESE, ELIZABETH CLAIRE DEES, Andrea Wang-Gillam · fiscal years 2014 to 2019Named on NCT03604978
Most cited trial papers
Clinical-trial papers with this author name in glioblastoma, ranked by citations from NIH iCite, fetched 2026-11-12 12:21 UTC. The ranking covers the 200 most relevant of 14 PubMed records, and a shared surname and initials can bring in a namesake. All 14 on PubMed
- 2,011 citationsRCR 50.0
- NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma.J Clin Oncol · 2023181 citationsRCR 18.7
- A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma.J Neurooncol · 201996 citationsRCR 4.0
- A phase I study to repurpose disulfiram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy.J Neurooncol · 201673 citationsRCR 2.5
- Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients.Cancer Chemother Pharmacol · 201254 citationsRCR 1.5
- Phase 1 trial, pharmacokinetics, and pharmacodynamics of dasatinib combined with crizotinib in children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma.Pediatr Blood Cancer · 201849 citationsRCR 1.7
- Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma.J Neurooncol · 201846 citationsRCR 1.8
- Impact of overall corticosteroid exposure during chemoradiotherapy on lymphopenia and survival of glioblastoma patients.J Neurooncol · 201938 citationsRCR 1.7
- 37 citationsRCR 3.8
- A Phase 1/2 Study of Disulfiram and Copper With Concurrent Radiation Therapy and Temozolomide for Patients With Newly Diagnosed Glioblastoma.Int J Radiat Oncol Biol Phys · 202435 citationsRCR 4.3